GSTM1 and Hepatic fibrosis: MAFLD was associated with higher Hb (adjusted odds ratio [aOR]: 1.91, 95% confidence interval [CI]: 1.17–3.13, p = 0.010), elevated γ-GT (aOR: 1.11, 95% CI: 1.02–1.21, p = 0.013), and significant liver fibrosis, namely F2, F3, and F4 (aOR: 31.25, 95% CI: 1.2–815.55, p = 0.039).